DWA
RETA

Delos Wealth Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Delos Wealth Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,600
Closed -$148K – 450
2021
Q4 		$148K Sell
5,600
-1,150
-17% -$89K 0.14% 45
2021
Q3 		$679K Hold
6,750
– – 0.75% 34
2021
Q2 		$955K Buy
+6,750
New +$762K 1.19% 29

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Delos Wealth Advisors's RETA Position: Q1 2022 in Review

Delos Wealth Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2022, closing a stake of 5,600 shares — an estimated $148K sold.

Delos Wealth Advisors first reported a position in RETA in Q2 2021 and held it in 3 quarters. The position peaked at $955K in Q2 2021. 149 funds tracked by Wall St. Rank hold RETA as of Q1 2022.

  • Delos Wealth Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2022 after selling out during the quarter.
  • Delos Wealth Advisors sold 5,600 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2022, an estimated $148K.
  • Delos Wealth Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2021 and held it in 3 quarters.
  • Delos Wealth Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $955K in Q2 2021.
  • 149 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2022.

Based on Delos Wealth Advisors's 13F filing for Q1 2022, filed 16 May 2022.